Flemming Ørnskov
Danish pharmaceutical executive (born 1958)
From Wikipedia, the free encyclopedia
Flemming Ørnskov (born 24 January 1958) is a Danish businessman. He has been the chief executive officer (CEO) of Galderma[3] since October 2019.
Flemming Ørnskov | |
|---|---|
| |
| Born | 24 January 1958[1] |
| Alma mater | University of Copenhagen INSEAD Harvard University |
| Occupations | CEO, Galderma |
| Children | 4 |
He was previously the CEO of Shire plc, a FTSE 100 specialty biopharmaceutical company as of 30 April 2013, succeeding Angus Russel.[4] He previously worked for Bayer, Bausch & Lomb and Novartis.[3]
He is also the non-executive chairman of Waters Corporation, a position he's been holding since 2017.[5][6]
Ørnskov was educated at the Esbjerg Gymnasium.[1] He received his MD from the University of Copenhagen, followed by an MBA from INSEAD, and a Master of Public Health (MPH) from Harvard University.[7] Ørnskov is qualified as a doctor in Denmark and has experience as a practicing hospital physician.[8]
Ørnskov led Galderma's IPO on the Zurich stock exchange on March 22, 2024, one of the biggest offerings in Europe in years and the biggest in Switzerland since 2017.[9][10] He declares Galderma plans to use the proceeds to pay down debt and invest in its pipeline.[11]
Ørnskov is married to a German management consultant, with whom he has two sons. He has one son and a daughter from a previous marriage.[2][1]
Awards
Top 100 Best-Performing CEOs in the World, 2015 - Harvard Business Review[12]
Top 25 Most Influential People in Biopharma Today, 2013 - Fierce Biotech[13]
.jpg){kind=small}